AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21974764
Drug: Valsartan 40-80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 40-80 mg
Trial: 11745199
Drug: Paclitaxel (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (135 mg/m2) over 24 hours with cisplatin (75 mg/m2) on a 21‐day cycle
Trial: 11745199
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m2) with gemcitabine (1 g/m2) on Days 1, 8, and 15 on a 28‐day cycle
Trial: 11745199
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m2) with docetaxel (75 mg/m2) on a 21‐day cycle
Trial: 11745199
Drug: Paclitaxel (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (225 mg/m2) over 3 hours with carboplatin (area under the curve, 6)
Trial: 8323380
Drug: Intervention not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention not specified, but involves treatment for rheumatoid arthritis with a focus on radiological progression.
Trial: 28040448
Drug: Belladonna and
RxNorm normalized name: BELLADONNA AND DERIVATIVES, PLAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belladonna and opium rectal suppositories (16.2/60 mg) administered rectally immediately after surgery and every 8 hours for a total of 3 doses.
Trial: 28040448
Drug: Placebo suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppositories administered rectally immediately after surgery and every 8 hours for a total of 3 doses.
Trial: 19756426
Drug: Placebo suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppositories
Trial: 28040448
Drug: Belladonna and
RxNorm normalized name: BELLADONNA AND DERIVATIVES, PLAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belladonna and opium rectal suppositories
Trial: 25270958
Drug: Etanercept (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (0.4 mg/kg twice weekly for 8 doses) plus systemic corticosteroids (2.0 mg/kg/day)
Trial: 21285990
Drug: Dexamethasone, Aspirin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone, Aspirin, and immediate addition of Diethylstilbestrol (DAiS)
Trial: 8704697
Drug: Low PC
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low PC pre-chemotherapy
Trial: 7491349
Drug: Long-term oxygen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oxygen therapy (LTOT)
Trial: 6432084
Drug: Dihydroergostin (DE‐145)
RxNorm normalized name: Dihydroergocristine
DrugBank: Dihydroergocristine (DB13345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergostin (DE‐145) 2 mg intravenous administration
Trial: 11966935
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of n-6 polyunsaturated fatty acids
Trial: 8918492
Drug: 5-FU dose
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU dose intensity > 1,400 mg/m2/wk over four courses
Trial: 1986658
Drug: Propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3 mg.kg‐1
Trial: 1986658
Drug: Propofol 5
RxNorm normalized name: propofol 500 MG in 50 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 5 mg.kg‐1
Trial: 1986658
Drug: Thiopental 5‐7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 5‐7 mg.kg‐1
Trial: 6642069
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of enteric-coated erythromycin base (Ery-Max) administered twice daily for 10 days
Trial: 6642069
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of enteric-coated erythromycin base (Ery-Max) administered four times daily for 10 days
Trial: 6642069
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with enteric-coated erythromycin base (Ery-Max)
Trial: 26897389
Drug: SMART regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART regimen (budesonide/formoterol 200/6-µg metered dose inhaler for maintenance and reliever therapy)
Trial: 26897389
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (salbutamol 100 µg 1-2 actuations for symptom relief)
Trial: 17498016
Drug: Rectal paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal paracetamol (20‐25 mg x kg(‐1)) at the third hour
Trial: 14634860
Drug: Maintenance iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance iron therapy (6 mg/kg per month)
Trial: 14634860
Drug: Intermittent iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent iron therapy (14.4 mg/kg per month)
Trial: 8403132
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia (SAB) with plain 0.5% bupivacaine (15 mg) and 0.2 mg epinephrine added
Trial: 8403132
Drug: Epidural anaesthesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural anaesthesia (AEA) with the same solution alkalinized with bicarbonate
Trial: 3042643
Drug: Etofenamate gel
RxNorm normalized name: etofenamate
DrugBank: Etofenamate (DB08984)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etofenamate gel
Trial: 10847536
Drug: Guided tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided tissue regeneration (GTR) treatment with a resorbable polylactic acid (PLA) barrier
Trial: 26508503
Drug: Iguratimod (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iguratimod (25 mg, twice daily, orally)
Trial: 18702903
Drug: Nasal douching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal douching with a 200‐mL nasal irrigation bottle (one standardized squeeze bilaterally)
Trial: 9725757
Drug: lorazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lorazepam (2 mg)
Trial: 12810142
Drug: Buprenorphine 1
RxNorm normalized name: buprenorphine 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 1 mg
Trial: 12810142
Drug: Methadone 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone 30 mg
Trial: 7775634
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (including placebo)
Trial: 16641430
Drug: FTC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTC plus CLV (200 mg FTC QD + 10 mg CLV QD)
Trial: 16641430
Drug: FTC alone
RxNorm normalized name: (-)-FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTC alone (200 mg FTC QD + placebo)
Trial: 10370615
Drug: Stop-flow thoracic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop-flow thoracic perfusion with systemic chemotherapy and inhalation IL-2 immunotherapy (Group B)
Trial: 10370615
Drug: Stop-flow thoracic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop-flow thoracic perfusion with systemic chemotherapy without inhalation IL-2 immunotherapy (Group A)
Trial: 21610124
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin treatment
Trial: 22963588
Drug: Exercise on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise on Prescription (EoP)
Trial: 11380069
Drug: Reference isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference isosorbide dinitrate sublingual tablet (5 mg)
Trial: 11380069
Drug: Test isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test isosorbide dinitrate sublingual tablet (5 mg)
Trial: 2233904
Drug: H. influenzae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine (PRP-D)
Trial: 452871
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of quinestrol (oral, one tablet once a month)
Trial: 452871
Drug: Placebo (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral, one tablet once a month)
Trial: 22018187
Drug: Prednisolone 5
RxNorm normalized name: prednisolone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 5 mg/day
Trial: 6148345
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose propranolol
Trial: 17241875
Drug: AT(1) receptor
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT(1) receptor antagonist losartan
Trial: 17241875
Drug: AT(1) receptor
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT(1) receptor antagonist candesartan
Trial: 15717509
Drug: Kinetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinetic therapy (KT) with propofol sedation
Trial: 10066989
Drug: Couples with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couples with 1 drug-abusing partner (husband or wife)
Trial: 10066989
Drug: Couples with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couples with both partners abusing drugs
Trial: 10066989
Drug: Couples with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couples with 1 drug-abusing partner during and 1 year after treatment
Trial: 7644246
Drug: Ondansetron (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (4 mg, 8 mg)
Trial: 973761
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment in 13 patients
Trial: 22776534
Drug: Escitalopram (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10-20 mg/d)
Trial: 15168289
Drug: V.A.C. therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V.A.C. therapy
Trial: 15556824
Drug: High-dose adenosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adenosine infusion (140 microg/kg/min for 22 minutes)
Trial: 15556824
Drug: Beta-endorphin bolus
RxNorm normalized name: beta-endorphin human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-endorphin bolus followed by infusion
Trial: 15556824
Drug: Naloxone bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone bolus followed by NaCl infusion
Trial: 15556824
Drug: Placebo (NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (NaCl bolus for 2 minutes followed by NaCl infusion for 15 minutes)
Trial: 31041523
Drug: CXL combined
RxNorm normalized name: CXL-1020
DrugBank: CXL-1020 (DB15326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CXL combined with antifungal medications (CXL‐M)
Trial: 31041523
Drug: Antifungal medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal medications alone (M)
Trial: 19262495
Drug: Amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5 mg day(-1) increased to 10 mg day(-1))
Trial: 18690917
Drug: 5‐HT and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT and NA reuptake inhibitors (e.g., duloxetine)
Trial: 9264050
Drug: Estazolam tablets
RxNorm normalized name: Estazolam Tablets
DrugBank: Estazolam (DB01215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estazolam tablets (reference formulation, ESILGAN)
Trial: 8319321
Drug: Nuelin SA
RxNorm normalized name: Nuelin S.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuelin SA (sustained-release theophylline) 250 mg every 12 h plus Nuelin liquid (non-sustained-release theophylline) 100 mg, 200 mg, or 300 mg
Trial: 8319321
Drug: Nuelin SA
RxNorm normalized name: Nuelin S.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuelin SA (sustained-release theophylline) 250 mg every 12 h plus placebo
Trial: 3621870
Drug: 0.01 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01 mg/kg b.w. of TGLVP
Trial: 15983221
Drug: Ruboxistaurin (RBX)
RxNorm normalized name: ethanol
DrugBank: Ruboxistaurin (DB11829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruboxistaurin (RBX) 32 mg/day
Trial: 12857503
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg esmolol combined with 2 microg/kg fentanyl (Group D)
Trial: 6367947
Drug: S1: CYVADIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S1: CYVADIC (combination chemotherapy with cyclophosphamide, vincristine, Adriamycin, and DTIC administered simultaneously every 4 weeks)
Trial: 6367947
Drug: S2: ADIC-CYV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S2: ADIC-CYV (pairs of drugs administered alternating at 4 weekly intervals)
Trial: 28265715
Drug: Suvorexant 40/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant 40/30 mg
Trial: 27397664
Drug: Suvorexant 20/15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant 20/15 mg
Trial: 15627725
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human leptin (4 microg ml(‐1) kg(‐1) body weight)
Trial: 7560254
Drug: Nefazodone 200
RxNorm normalized name: NEFAZODONE 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone 200 mg every 12 hours (n = 12)
Trial: 7560254
Drug: Nefazodone 200
RxNorm normalized name: NEFAZODONE 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone 200 mg every 12 hours
Trial: 7560254
Drug: Warfarin daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin daily for 14 days
Trial: 2182370
Drug: No endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No endoscopic therapy (Control)
Trial: 31154289
Drug: Etanercept (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (50 mg, s.c., weekly) + Methotrexate (7.5-15 mg, p.o., weekly)
Trial: 31154289
Drug: Monotherapy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy group (Etanercept)
Trial: 28060936
Drug: Royal Jelly
RxNorm normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Royal Jelly (RJ) 1200 mg/tablet, six tablets daily for 8 weeks
Trial: 30501611
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% with 0.1 mg/kg dexamethasone
Trial: 20487046
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (dutasteride 0.5 mg + tamsulosin 0.4 mg)
Trial: 19013011
Drug: Dutasteride monotherapy
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dutasteride monotherapy
Trial: 23234237
Drug: Multifaceted educational
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted educational intervention for GPs on performing a narrative doctor-patient dialogue and medication review.
Trial: 16705491
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) for 4 hours/week for two weeks after standard job search assistance for two weeks
Trial: 14617595
Drug: Remifentanil with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil with morphine
Trial: 9184402
Drug: PEG-Hirudin 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-Hirudin 0.05 to 0.6 mg/kg subcutaneous doses
Trial: 9184402
Drug: PEG-Hirudin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-Hirudin 0.2 to 0.4 mg/kg once daily subcutaneous for five days
Trial: 9184402
Drug: PEG-Hirudin 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-Hirudin 0.3 mg/kg i.v. bolus followed by daily s.c. injections
Trial: 8264145
Drug: Simvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10 mg/day, increasing to 20 to 40 mg/day as required)
Trial: 3987180
Drug: Intravenous nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous nifedipine infusion (4.5 mg in 45 minutes)
Trial: 26460743
Drug: Delayed loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed loaded 1P implants
Trial: 22864465
Drug: Creatine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (5 g/day)
Trial: 16312177
Drug: FCT SQV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCT SQV (two 500 mg tablets)
Trial: 16312177
Drug: HC SQV
RxNorm normalized name: Casporyn HC
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HC SQV (five 200 mg capsules)
Trial: 12732885
Drug: Standard-dose (SD)
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose (SD) CSA
Trial: 8733205
Drug: High treatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High treatment specificity and high delta sleep ratio
Trial: 8733205
Drug: Low treatment
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low treatment specificity and low delta ratio
Trial: 26434752
Drug: Pharmacist involvement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist involvement (face-to-face medication reconciliation, patient-specific pharmaceutical care plan, discharge counseling, postdischarge phone calls on days 3, 14, and 30)
Trial: 20370970
Drug: Cognitive restructuring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive restructuring and/or exposure therapy
Trial: 9412547
Drug: Zafirlukast (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast (20 mg)
Trial: 7862229
Drug: Enoxaparin at
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin at a dose of 0.5 mg/kg (50 U1 Anti‐Xa/kg)
Trial: 15795700
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (omeprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + furazolidone 100 mg 2 tab. bid + tetracycline 250 mg 2 cap. bid)
Trial: 8953674
Drug: alpha-streptococci spray
RxNorm normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-streptococci spray treatment for at least 5 days
Trial: 30877484
Drug: Duloxetine 30-60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 30-60 mg per day for 4 weeks
Trial: 30877484
Drug: Pregabalin 75-150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 75-150 mg per day for 4 weeks
Trial: 23797771
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (CT)
Trial: 6451235
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg daily)
Trial: 20703230
Drug: Olmesartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (40 mg per day)
Trial: 20703230
Drug: Imidapril (2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidapril (2.5-10 mg per day) added to valsartan (160 mg per day)
Trial: 9803047
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) oxycodone 15 mg four times daily
Trial: 9803047
Drug: Both CR
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both CR and IR oxycodone
Trial: 8919986
Drug: Cumulative dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative dosage method (group I, 33 patients)
Trial: 25673441
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A (four-drug FDC)
Trial: 25673441
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B (two-drug FDC)
Trial: 25673441
Drug: Formulation C
RxNorm normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation C (two-drug FDC)
Trial: 25673441
Drug: Formulation D
RxNorm normalized name: Complete Formulation D3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation D (two-drug FDC)
Trial: 19075260
Drug: Risedronate 35
RxNorm normalized name: risedronate 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 35 mg weekly
Trial: 2612203
Drug: Amoxycillin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin plus clavulanic acid (250 or 500 mg amoxycillin and 62.5 or 125 mg clavulanic acid) 3-times daily
Trial: 23757427
Drug: Closed-loop (CL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop (CL) insulin delivery
Trial: 17482982
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (3 mg/kg per day)
Trial: 11675958
Drug: Arotinolol 10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arotinolol 10-20 mg twice daily for 4 weeks
Trial: 23086524
Drug: Rapid weight
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid weight loss (RWL) preparation with very low calorie diet